"...[PK] actionable correlation study..." This is the 12-month dose dependency, and presumably the efficacy correlation for AD (disease stage, +/- DZP, etc for sub group stratification). So that is what's coming. I hope they find meaningful correlation.
IMO - Failure to meed Biogen's tests may just mean that it isn't going to rescue Opicinumab. Missling may not have offered anything more than a combo drug.
News 
Market Data 
Discover 
